{"success":true,"data":{"pressRelease":{"id":"156573","rtpr_id":"nGNX7JZDpX-20260930","ticker":"IMM","exchange":"ASX","all_tickers":["IMM"],"title":"Immutep Receives ~A$0.86 Million R&D Tax Incentive","author":"Globe Newswire","published_at":"2026-09-30T12:00:00.206Z","article_body":"SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited\n(https://www.globenewswire.com/Tracker?data=-cgvcWuRg1NDnCqScZX0Ee5NMVvnq2sAfuJlD8_HnBdR4krIsck7_bK-Jpdglf9qwezHaEWnGPE0LY8ZDA_69QAy6aKreJYTvO8IzB0oTDU=)\n(ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage\nimmunotherapy company targeting cancer and autoimmune diseases, today\nannounces that it received an A$856,669 cash rebate from the Australian\nFederal Government’s R&D tax incentive program. The cash rebate was provided\nin respect of expenditure incurred on eligible R&D activities conducted in the\n2025 fiscal year.\n\nThis follows approval from AusIndustry of Immutep’s application for an\nAdvance overseas finding. Due to the Advance overseas finding, certain of\nImmutep’s overseas research and development activities were eligible for the\nR&D Tax Incentive, in addition to its eligible Australian activities.\n\nImmutep also receives the French CIR tax incentive through its subsidiary\nImmutep S.A.S. in respect of expenditure incurred on eligible R&D activities\nconducted in the European Union.\n\nIn addition, Immutep is eligible for Germany’s R&D tax incentive program\n(Forschungszulage) in respect of qualifying internal R&D personnel costs of\nits German subsidiary, Immutep GmbH. Having received its first payment under\nthis program in Q4 FY26, Immutep may receive further Forschungszulage payments\nin future years in respect of eligible R&D activities. Any such payments\nremain subject to the statutory application, assessment and review process,\nand their amount and timing are uncertain.\n\nImmutep will apply the non-dilutive funding towards furthering its current R&D\nactivities for its product candidates, efti and IMP761. The expected cash\nreach of the Company extends into the first half of CY2028.\n\nAbout Immutep\nImmutep is a late-stage biotechnology company developing novel immunotherapies\nfor cancer and autoimmune disease. The Company is a pioneer in the\nunderstanding and advancement of therapeutics related to Lymphocyte Activation\nGene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s\nability to stimulate or suppress the immune response. Immutep is dedicated to\nleveraging its expertise to bring innovative treatment options to patients in\nneed and to maximise value for shareholders. For more information, please\nvisit www.immutep.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements, including statements\nregarding the intended use of the R&D tax incentive funding, the Company’s\neligibility for and receipt of potential future R&D tax incentive payments,\nincluding under Germany’s Forschungszulage, the Company’s expected cash\nreach, anticipated clinical development, regulatory progress and the potential\nbenefits of efti and IMP761. These forward-looking statements are based on\ncurrent expectations, estimates and projections, and involve known and unknown\nrisks, uncertainties and other important factors that could cause actual\nresults to differ materially from those expressed or implied in such\nstatements.\n\nFactors that could cause actual results to differ materially include risks\nassociated with clinical trial outcomes, regulatory developments, the cost and\ntiming of the Company’s clinical programs, the availability of future\nfunding, and the Company’s ability to advance its product candidates.\n\nReaders are cautioned not to place undue reliance on forward-looking\nstatements, which speak only as of the date of this release. Immutep\nundertakes no obligation to update or revise such statements, except as\nrequired by applicable law.\n\nDisclaimer\nThis announcement has been prepared for informational purposes only and does\nnot constitute an offer to sell, or a solicitation of an offer to buy,\nsecurities in any jurisdiction.\n\nAustralian Investors/Media:\nEleanor Pearson, Sodali & Co.\n+61 2 9066 4071; eleanor.pearson@sodali.com\n\nUS Investors/Media:\nMatthew Beck, astr partners\n+1 (917) 415-1750; matthew.beck@astrpartners.com\n\nThis announcement was authorised for release by the CEO of Immutep Limited.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2cd55d0-59ab-45ac-a1fe-5cf2adac7f24)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7JZDpX-20260930","title":"Immutep Receives ~A$0.86 Million R&D Tax Incentive","author":"Globe Newswire","ticker":"IMM","created":"2026-09-30T12:00:00.206Z","tickers":["IMM"],"exchange":"ASX","article_body":"SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited\n(https://www.globenewswire.com/Tracker?data=-cgvcWuRg1NDnCqScZX0Ee5NMVvnq2sAfuJlD8_HnBdR4krIsck7_bK-Jpdglf9qwezHaEWnGPE0LY8ZDA_69QAy6aKreJYTvO8IzB0oTDU=)\n(ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage\nimmunotherapy company targeting cancer and autoimmune diseases, today\nannounces that it received an A$856,669 cash rebate from the Australian\nFederal Government’s R&D tax incentive program. The cash rebate was provided\nin respect of expenditure incurred on eligible R&D activities conducted in the\n2025 fiscal year.\n\nThis follows approval from AusIndustry of Immutep’s application for an\nAdvance overseas finding. Due to the Advance overseas finding, certain of\nImmutep’s overseas research and development activities were eligible for the\nR&D Tax Incentive, in addition to its eligible Australian activities.\n\nImmutep also receives the French CIR tax incentive through its subsidiary\nImmutep S.A.S. in respect of expenditure incurred on eligible R&D activities\nconducted in the European Union.\n\nIn addition, Immutep is eligible for Germany’s R&D tax incentive program\n(Forschungszulage) in respect of qualifying internal R&D personnel costs of\nits German subsidiary, Immutep GmbH. Having received its first payment under\nthis program in Q4 FY26, Immutep may receive further Forschungszulage payments\nin future years in respect of eligible R&D activities. Any such payments\nremain subject to the statutory application, assessment and review process,\nand their amount and timing are uncertain.\n\nImmutep will apply the non-dilutive funding towards furthering its current R&D\nactivities for its product candidates, efti and IMP761. The expected cash\nreach of the Company extends into the first half of CY2028.\n\nAbout Immutep\nImmutep is a late-stage biotechnology company developing novel immunotherapies\nfor cancer and autoimmune disease. The Company is a pioneer in the\nunderstanding and advancement of therapeutics related to Lymphocyte Activation\nGene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s\nability to stimulate or suppress the immune response. Immutep is dedicated to\nleveraging its expertise to bring innovative treatment options to patients in\nneed and to maximise value for shareholders. For more information, please\nvisit www.immutep.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements, including statements\nregarding the intended use of the R&D tax incentive funding, the Company’s\neligibility for and receipt of potential future R&D tax incentive payments,\nincluding under Germany’s Forschungszulage, the Company’s expected cash\nreach, anticipated clinical development, regulatory progress and the potential\nbenefits of efti and IMP761. These forward-looking statements are based on\ncurrent expectations, estimates and projections, and involve known and unknown\nrisks, uncertainties and other important factors that could cause actual\nresults to differ materially from those expressed or implied in such\nstatements.\n\nFactors that could cause actual results to differ materially include risks\nassociated with clinical trial outcomes, regulatory developments, the cost and\ntiming of the Company’s clinical programs, the availability of future\nfunding, and the Company’s ability to advance its product candidates.\n\nReaders are cautioned not to place undue reliance on forward-looking\nstatements, which speak only as of the date of this release. Immutep\nundertakes no obligation to update or revise such statements, except as\nrequired by applicable law.\n\nDisclaimer\nThis announcement has been prepared for informational purposes only and does\nnot constitute an offer to sell, or a solicitation of an offer to buy,\nsecurities in any jurisdiction.\n\nAustralian Investors/Media:\nEleanor Pearson, Sodali & Co.\n+61 2 9066 4071; eleanor.pearson@sodali.com\n\nUS Investors/Media:\nMatthew Beck, astr partners\n+1 (917) 415-1750; matthew.beck@astrpartners.com\n\nThis announcement was authorised for release by the CEO of Immutep Limited.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2cd55d0-59ab-45ac-a1fe-5cf2adac7f24)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T12:00:00.351572542Z","server_sent_at_ms":1790769600351},"received_at":"2026-09-30T12:00:00.402Z","source_url":null},"analysis":{"id":"145263","press_release_id":"156573","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Immutep received an A$856,669 cash rebate under the Australian Federal Government's R&D tax incentive program for eligible FY2025 R&D spending.\n\nEligibility was broadened by an AusIndustry-approved Advance overseas finding covering certain offshore R&D, and the company also receives French CIR incentives and first payments under Germany's Forschungszulage.\n\nThe non-dilutive funding will support development of efti and IMP761, with the company's cash reach extending into the first half of CY2028.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small non-dilutive tax rebate modestly extends runway for LAG-3 pipeline funding."},"keyFigures":{"customDimensions":{"cash_runway":"cash reach extends into first half of CY2028","rd_tax_rebate_aud":856669}},"namedEntities":{"people":[{"name":"Eleanor Pearson","role":"Australian investors/media contact, Sodali & Co."},{"name":"Matthew Beck","role":"US investors/media contact, astr partners"}],"products":["efti","IMP761"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"filer"},{"name":"Immutep S.A.S.","relationship":"subsidiary"},{"name":"Immutep GmbH","relationship":"subsidiary"},{"name":"AusIndustry","relationship":"government agency"}],"dollarAmounts":[{"amount":"A$856,669","context":"Australian R&D tax incentive cash rebate for FY2025 R&D expenditure"}]},"materialImpact":{"score":1,"reasoning":"A routine, small (~A$0.86M) non-dilutive R&D tax rebate with no change to clinical or financial outlook. Confirms cash reach into 1H CY2028 but is not market-moving."},"tickerRelevance":{"others":[{"ticker":"IMMP","relevance":"NASDAQ listing of the same company"}],"primary":"IMM"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","nonDilutive":true,"eventGravity":"routine tax rebate"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"Immutep received an A$856,669 cash rebate under the Australian Federal Government's R&D tax incentive program for eligible FY2025 R&D spending.\n\nEligibility was broadened by an AusIndustry-approved Advance overseas finding covering certain offshore R&D, and the company also receives French CIR incentives and first payments under Germany's Forschungszulage.\n\nThe non-dilutive funding will support development of efti and IMP761, with the company's cash reach extending into the first half of CY2028.","key_figures":{"customDimensions":{"cash_runway":"cash reach extends into first half of CY2028","rd_tax_rebate_aud":856669}},"named_entities":{"people":[{"name":"Eleanor Pearson","role":"Australian investors/media contact, Sodali & Co."},{"name":"Matthew Beck","role":"US investors/media contact, astr partners"}],"products":["efti","IMP761"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"filer"},{"name":"Immutep S.A.S.","relationship":"subsidiary"},{"name":"Immutep GmbH","relationship":"subsidiary"},{"name":"AusIndustry","relationship":"government agency"}],"dollarAmounts":[{"amount":"A$856,669","context":"Australian R&D tax incentive cash rebate for FY2025 R&D expenditure"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T12:00:05.524Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap biotech","nonDilutive":true,"eventGravity":"routine tax rebate"}},"durationMs":5109,"modelName":"glm-5.3-flashx"}}